For MedTech founders & commercial leaders

Your device works.
Your team is ready.
So why aren't the numbers moving?

The launch happened. The training was delivered. The investment was made. And then — silence. No single answer fits every situation. But there is almost always a system that nobody fully mapped before it was entered.

Start a conversation Read the real story →
A bird breaking free from its shell — the moment of emergence

After a stocking launchOrders placed, training done, reps in territory. Six months later — utilisation nowhere near target and nobody can say exactly why.

Before market entryYou want the commercial and clinical architecture built correctly before the pressure is on — not fixed after the first six months have cost you.

Under board pressureThe numbers aren't following the investment. The board wants an answer. You need someone who has been in that room and knows what to look for.

The truth, from inside the room

I've been here.
Many times.

I've worked inside multiple product launches — direct sales, distributor models, the full cycle. I know what it looks like when a launch is done properly: the stocking orders come in, the launch event runs well, the training is delivered, the reps are in territory, the investment is committed.

And then the sales don't follow.

What I learned — slowly, across multiple situations, through the pressure of those board meetings — is that there is no single answer. The problem is never identical. What is consistent is this: somewhere in the system, someone who needed to move didn't move. And nobody had mapped who that was before the launch began.

Not just the surgeon. The procurement lead whose budget was affected and who nodded in the meeting and then quietly did nothing. The theatre coordinator whose workflow would change and who was never asked. The department head whose economic case was built for the wrong audience. The system sell — getting every part of the human system aligned — is the work that almost nobody does before launch, and almost everybody has to scramble to do after.

Lumenara exists because I've been in those scrambles enough times to know what it costs — in time, in investment, in board relationships — and to know that most of it is preventable.

What we know from experience

"The launch went well. The clinical champion is committed. The sales team is working the accounts. And yet — six months in — utilisation isn't where it should be, and nobody can quite explain why."

"This is not a failure of the device. This is almost always a failure to map the system around the device — before it arrived."

This is the conversation Lumenara was built for. Not the post-mortem. The prevention — and when prevention has passed, the diagnosis and recovery. We bring both commercial experience and active clinical practice into the same conversation, because the system that needs to be mapped is both commercial and clinical at once.
What changes

Not features.
Outcomes.

Three shifts that happen when the system is mapped before the pressure arrives.

Before
"We can't explain why the numbers aren't following"
↓
After
You know exactly where the friction is — and who needs to move first
Not a theory. A named stakeholder, a specific concern, a concrete next conversation. The invisible becomes visible.
Before
"The plan looks right — but keeps meeting the market wrong"
↓
After
The commercial plan has been tested against clinical reality — before it goes live
When the person building the commercial strategy has also stood inside the system it enters, the surprises don't survive the planning stage.
Before
"We're under board pressure and running out of time"
↓
After
A clear diagnosis, a credible plan, and someone who has navigated this before
Not reassurance. A real assessment of what went wrong, what can be fixed, and in what sequence — delivered by someone who has sat in those board meetings too.
"The gap between approval and adoption is almost never about the device. It is about whether the whole system was mapped — before the device entered it."
Arun Kumar · Founder, Lumenara
How we approach it

Four stages.
One outcome.

We don't start with a proposal. We start with the question most advisors skip.

1
Pause
Before scaling or pushing harder — stop. An honest assessment of where the friction actually is, not where it appears to be or where the pressure is pointing. This is the step most teams skip because the pressure to move prevents it.
2
Map
Every stakeholder in the system — not just the clinical champion. Procurement, theatre coordination, nursing, finance, department leadership. For each: their real concern, their real blocker, what they actually need to move. This map is what most commercial plans are built without.
3
Design
Build the conditions for adoption deliberately — workflow integration, training architecture, economic justification by audience, the correct sequencing of who moves first. This is the system sell. It is the plan most companies never build before launch.
4
Embed
Stay inside the system until adoption holds. Not until the report is delivered. Not until the engagement ends. Until the numbers are moving and the conditions are self-sustaining without us.
Who we work with

Three moments where
this conversation matters most

We work across device types and commercial stages — but there are three situations where the work tends to make the most difference.

Before launch — building it right

CE mark or UKCA cleared. Clinical evidence solid. About to enter UK or European markets. You want to do the system sell properly before the investment is made — not correct it after six months of stalled utilisation.

Pre-launchCE / UKCA clearedUK or EU entry

Post-launch stall — finding what went wrong

Launch done. Training delivered. Reps in territory. Utilisation not moving. Something in the system didn't engage — and nobody has been able to name it precisely enough to fix it.

Post-launchStalled utilisationBoard pressure

Scaling — taking what works into new systems

Adoption is working in one context. Now you need to scale that — across a health system, a country, or into Europe. What worked in one system needs to be rebuilt for the next one, not assumed to transfer.

Proven adoptionScaling phaseEMEA expansion

Two streams. One conversation.

Clinical intelligence

Active surgical practice — real-time insight from inside the system your device is entering. When we map a surgical workflow, we're drawing on what actually happens in the theatre. Not what the protocol says should happen. That difference is where the real blockers live.

Commercial intelligence

Direct experience across multiple launches — direct sales, distributor models, system sells, board pressure. Not advisory from a distance. Operational experience of what the stocking order, the training programme, and the six-month review actually feel like from the inside.

"Both perspectives. In the same room. Working the same problem — before the numbers stop moving."

What we do

Four ways
we engage

Each one built around the same question: what does this specific device, in this specific system, at this specific stage, actually need next?

Clinical Adoption Strategy

The full system sell — mapping every stakeholder, their real concern, and what it takes to move each one from approval or stocking order to active, sustained use.

  • Full stakeholder landscape mapping
  • Blocker identification and resolution design
  • Workflow integration planning
  • Training architecture by role
  • Adoption monitoring and stabilisation

Early Market Architecture

Phase 1 commercial sequencing for device companies entering UK and European markets — building the conditions for adoption before the investment is committed.

  • Market access pathway design
  • Phase 1 sequencing and prioritisation
  • Investor-ready commercial narrative
  • Health economic evidence strategy
  • NHS and AHSN engagement planning

Commercial & Clinical Advisory

Ongoing strategic partnership — senior commercial experience and active surgical practice working together on the same problem, for as long as both are needed.

  • Commercial strategy and execution support
  • Clinical reality-testing of commercial plans
  • KOL development and centre of excellence
  • European market entry strategy
  • EU MDR and UKCA commercial navigation

Adoption Recovery

For device companies where utilisation has stalled after launch — a clear diagnostic of what actually went wrong, and a re-sequenced plan built on solid ground, not optimism.

  • Root cause diagnostic assessment
  • Stakeholder relationship reset
  • Workflow and training redesign
  • Economic case reconstruction by audience
  • Re-sequenced adoption programme
Common questions

What people ask
at the start

Honest answers to the questions we hear before almost every engagement begins.

Most devices that underperform after regulatory approval are not let down by the technology. They are let down by the planning that surrounds it. The stocking orders, the launch, the training — those happen. What doesn't happen is a complete mapping of the human system the device is entering: procurement concerns, theatre coordinator workflows, nursing team training needs, department head economics. If any one of those stakeholders is not addressed, adoption quietly stalls. This is a planning and process problem, not a product problem.
No. And anyone who offers you one is selling a methodology, not a diagnosis. The problem is never identical across launches. What is consistent is that somewhere in the system, someone who needed to engage didn't engage — and nobody had identified that person before the launch began. The answer is always specific to that system, that device, that organisation, and that moment. Which is why it requires someone who can read the system rather than apply a standard template.
Clinical adoption intelligence is the discipline of understanding and designing for everything that happens between device approval and consistent real-world utilisation. It combines commercial strategy — stakeholder mapping, economic narrative, sequencing — with active clinical knowledge of how devices actually function inside surgical teams, hospital workflows, and procurement systems. Lumenara brings both into the same conversation so the plan is tested against both realities before launch pressure begins.
Most MedTech advisory draws on commercial experience alone. Lumenara combines direct operational experience across multiple launches — direct sales, distributor models, system sells, board pressure — with active surgical practice. That means the commercial plan is stress-tested against clinical reality before it meets the market. And the diagnosis, when things have stalled, comes from someone who has been inside those situations, not someone who has read about them.
Every engagement follows four stages: Pause — honest assessment of where friction actually exists, not where it appears to be. Map — stakeholder by stakeholder identification of real concerns and real blockers, building the complete picture of the system sell that needs to happen. Design — deliberate construction of adoption conditions covering workflow, training, economics, and sequencing. Embed — staying inside the system until adoption holds, not until the report is delivered.
NHS device adoption timelines vary by product class and evidence base. Class IIa devices with strong real-world evidence and clear workflow fit can achieve AHSN adoption within 18-24 months of UKCA clearance. Devices requiring NICE guidance typically require 3-4 years. The most common cause of delay is failing to address non-clinical stakeholders — procurement, finance, theatre management — whose concerns are as decisive as clinical champion support, and who are often never mapped before launch.
Start the conversation

If you recognise
any of this —
let's talk.

Not a discovery call that ends in a proposal. A real conversation about where you are, what the system looks like, and whether we're the right people to help you map it.

Tell us the situation. We'll tell you what we see — honestly, even if what we see is that you don't need us.

arun@lumenara.co.uk
+44 (0)7763 911 139
lumenara.co.uk